CTE Session 1
Technologists Committee / Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Accessible on-demand at any time

Session Title
Tech Guide Launch

Chairperson
Agata Pietrzak (Poznan, Poland)

Programme
29 min  J. Tyler Middlebrooks (Benton, United States of America /SNMMI): PET/CT Artefacts and Pitfalls
29 min  Andrej Doma (Ljubljana, Slovenia): New Solutions in Oncology
29 min  Donatienne Van Weehaeghe (Leuven, Belgium): Advancements in Neuroimaging
3 min  Session Summary by Chairperson

Educational Objectives
1. Describe the possible PET and CT artefacts, outline the origin of the artefacts and the possibilities to prevent them.
2. Characterize the influence of the technical novelties on the overall quality of the picture and study outcome.
3. Address and explain how PET/CT has been increasingly replacing conventional Nuclear medicine imaging in certain areas of clinical oncology.
4. Outline the recent advancements/guidelines in PET/CT utilization for radiotherapy planning.
5. Shortly overview the radiopharmaceuticals used in brain imaging.
6. Describe the possibilities for Brain imaging to diagnose ALS.

Summary
PET/CT study using various radiopharmaceuticals has become a method of choice in oncological diseases management. Medical imaging's evolving technology demands the constant improvement of existing solutions while simultaneously eliminating the current method's limitations. This year’s Tech Guide aims to provide a technical and clinical overview of PET/CT utilities and the most recent innovations improving study outcomes. The session offers viewers the clinical and technical basics up to the most critical novelties, while the value of technologists' knowledge and experience in PET/CT procedures planning and performance is highlighted.

A joint session with the SNMMI partners shows the importance and opportunity of international collaboration as significantly benefitting improving the PET/CT method as a necessary solution in oncological management.

Key Words
Artefacts, cardiac imaging, oncology, PET/CT, radiopharmaceuticals